American Society of Hirudotherapy

Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study

Research article published in Thrombosis and haemostasis (2020)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureSalivary PharmacologyBärnthaler T et al. · Thrombosis and haemostasis, 2020

Abstract

BACKGROUND:  For patients treated with dual antiplatelet therapy, standardized drug-specific 3-to-7 day cessation is recommended prior to major surgery to reach sufficient platelet function recovery. Here we investigated the hypothesis that supplemental fibrinogen might mitigate the inhibitory effects of antiplatelet therapy. METHODS AND RESULTS:  To this end blood from healthy donors was treated in vitro with platelet inhibitors, and in vitro thrombus formation and platelet activation were assessed. Ticagrelor, acetylsalicylic acid, the combination of both, and tirofiban all markedly attenuated the formation of adherent thrombi, when whole blood was perfused through collagen-coated microchannels at physiological shear rates. Addition of fibrinogen restored in vitro thrombus formation in the presence of antiplatelet drugs and heparin. However, platelet activation, as investigated in assays of P-selectin expression and calcium flux, was not altered by fibrinogen supplementation. Most importantly, fibrinogen was able to restore in vitro thrombogenesis in patients on maintenance dual antiplatelet therapy after percutaneous coronary intervention. CONCLUSION:  Thus, our in vitro data support the notion that supplementation of fibrinogen influences the perioperative hemostasis in patients undergoing surgery during antiplatelet therapy by promoting thrombogenesis without significantly interfering with platelet activation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAgedAspirinCalcium SignalingFemaleFibrinogenHemorheologyHeparinHirudinsHumansIn Vitro TechniquesMaleMiddle AgedP-SelectinPlatelet ActivationPlatelet Aggregation InhibitorsThrombosisTicagrelorTirofiban

Summary

In vitro, adding fibrinogen restored thrombus formation in blood treated with antiplatelet drugs (ticagrelor, aspirin, tirofiban) and in patients on dual antiplatelet therapy after PCI, without altering platelet activation markers.

Context

This in vitro study investigated whether supplemental fibrinogen could restore thrombus formation in whole blood from healthy donors treated with platelet inhibitors (ticagrelor, acetylsalicylic acid, tirofiban, and combinations) plus heparin, using collagen-coated microchannels at physiological shear rates. Fibrinogen restored thrombogenesis without altering platelet activation markers (P-selectin, calcium flux), and showed similar restorative effects in patients on maintenance dual antiplatelet therapy after percutaneous coronary intervention. The abstract does not mention hirudin, leech-derived components, or therapeutic leeching; heparin is the anticoagulant studied.

Citation

Reference (Vancouver style)

Bärnthaler T, Mahla E, Toth GG, Schuligoi R, Prüller F, Buschmann E, et al. Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study. Thromb Haemost. 2020;120(11):1548-1556. doi:10.1055/s-0040-1715445. PMID: 32772348

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.